Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
120511-73-1
Molecular formula
C17H19N5
Molecular weight
293.4 g/mol
Drug class
Aromatase Inhibitor
Mechanism of action
Aromatase Inhibitors [MoA]
Indications / reported uses
Breast Neoplasms
advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy
Drug class, mechanism of action and general use cases
Drug class
Aromatase Inhibitor
Mechanism of action
Aromatase Inhibitors [MoA]
General use cases
Breast Neoplasms
advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
Assessment scope
Project-specific PDE/ADE and OEL/OEB support
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Anastrozole PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Anastrozole Permitted Daily Exposure (PDE) report (the Anastrozole PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Anastrozole Occupational Exposure Limit (OEL) report (the Anastrozole OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.